Management of Metastatic Disease in Long Bones.

J Orthop Trauma

Division of Adult Reconstruction and Orthopedic Oncology, The CORE Institute, Phoenix, AZ.

Published: September 2022

Therapeutic Level V. See Instructions for Authors for a complete description of levels of evidence.

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOT.0000000000002360DOI Listing

Publication Analysis

Top Keywords

management metastatic
4
metastatic disease
4
disease long
4
long bones
4
bones therapeutic
4
therapeutic level
4
level instructions
4
instructions authors
4
authors complete
4
complete description
4

Similar Publications

Rationale: Established coronary artery disease (CAD) patients are at increased risk for recurrence of cardiovascular events and mortality due to non-attainment of recommended risk factor control targets.

Objective: We aimed to evaluate the attainment of treatment targets for risk factor control among CAD patients as recommended in the Indonesian CVD prevention guidelines.

Methods: Patients were consecutively recruited from the Makassar Cardiac Center at Wahidin Sudirohusodo Hospital, Indonesia.

View Article and Find Full Text PDF

Aim(s): This study aims to evaluate the workload of clinical nurses by measuring the work relative value (work RVU) of common nursing items based on the resource-based relative value scale in China.

Background: Various single measurements have been employed to measure the nursing workload, but no comprehensive method has yet to be developed in China.

Methods: A descriptive study was conducted to construct a common item set for nursing work in general wards on the basis of the 2019 History Information System nursing database from Class A tertiary hospitals to identify the time associated with each service.

View Article and Find Full Text PDF

This multicenter study explored the survival benefits of upfront primary tumor resection (PTR) followed by first-line cetuximab plus chemotherapy in real-world patients with wild-type metastatic colorectal cancer (mCRC). Treatment options for mCRC include chemotherapy, targeted therapy, immunotherapy, and surgery. The efficacy of upfront PTR in managing mCRC remains unclear.

View Article and Find Full Text PDF

Androgen receptor (AR) signaling is a target in prostate cancer therapy and can be treated with non-steroidal anti-androgens (NSAA) including enzalutamide, and apalutamide for patients with advanced disease. Metastatic castration-resistant prostate cancer (mCPRC) develop resistance becomes refractory to therapy limiting patient overall survival. Darolutamide is a novel next-generation androgen receptor-signaling inhibitor that is FDA approved for non-metastatic castration resistant prostate cancer (nmCRPC).

View Article and Find Full Text PDF

Background: Atrial fibrillation (AF) has a significant impact on health and quality of life. The relationship of AF burden and temporal patterns of AF on patient symptoms, outcomes, and healthcare utilization is unknown. Insertable cardiac monitors (ICMs) are a strategic and as yet untapped, tool to investigate these relationships.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!